Filana Therapeutics (FLNA) Net Cash Flow (2010 - 2026)
Filana Therapeutics (FLNA) posted quarterly Net Cash Flow of -$3.8 million for Q2 2026, up 22.46% year-over-year from -$3.1 million in Q2 2025, and up 57.0% quarter-over-quarter from -$9.0 million in Q1 2026.
Filana Therapeutics (FLNA) Net Cash Flow (2010 - 2026) Analysis & Trends
Filana Therapeutics' Net Cash Flow history runs 17 years deep, the most recent figure standing at -$3.8 million for Q2 2026.
- In Q2 2026, Net Cash Flow rose 22.46% year-over-year to -$3.8 million; the TTM figure through Jun 2026 stood at -$29.7 million (up 68.69% YoY), while the FY2025 annual figure was -$33.1 million, down 545.28% from the prior year.
- Net Cash Flow for Q2 2026 stood at -$3.8 million, up from -$9.0 million in the prior quarter.
- The five-year high for Net Cash Flow was $83.1 million in Q2 2024, with the low at -$60.4 million in Q4 2024.
- The 5-year median for Net Cash Flow is -$11.9 million (2022), against an average of -$8.4 million.
- The sharpest annual moves came in 2024 and 2025: Net Cash Flow surged 536.65% in 2024, then plunged 470.79% in 2025.
- Filana Therapeutics' Net Cash Flow stood at $26.4 million in 2022, then sank by 180.5% to -$21.2 million in 2023, then sank by 184.57% to -$60.4 million in 2024, then jumped by 82.4% to -$10.6 million in 2025, then jumped by 63.78% to -$3.8 million in 2026.
- Business Quant data shows FLNA's Net Cash Flow at -$3.8 million in Q2 2026, -$9.0 million in Q1 2026, and -$10.6 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 652.90 Mn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | -504.30 Mn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -183.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 407.41 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | -496,000.00 |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -37.14 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 225.59 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -2.83 Bn |
| 10 | Filana Therapeutics | 45.29 Mn | 45.29 Mn | - | -3.85 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -3.85 Mn |
| Jun 30, 2026 | -3.85 Mn |
| Mar 31, 2026 | -8.95 Mn |
| Mar 31, 2026 | -8.95 Mn |
| Dec 31, 2025 | -10.63 Mn |
| Dec 31, 2025 | -10.63 Mn |
| Sep 30, 2025 | -6.28 Mn |
| Sep 30, 2025 | -6.28 Mn |
| Jun 30, 2025 | -4.96 Mn |
| Jun 30, 2025 | -4.96 Mn |
| Mar 31, 2025 | -11.25 Mn |
| Mar 31, 2025 | -11.25 Mn |
| Dec 31, 2024 | -60.37 Mn |
| Dec 31, 2024 | -60.37 Mn |
| Sep 30, 2024 | -18.32 Mn |
| Sep 30, 2024 | -18.32 Mn |
| Jun 30, 2024 | 83.09 Mn |
| Jun 30, 2024 | 83.09 Mn |
| Mar 31, 2024 | 3.03 Mn |
| Mar 31, 2024 | 3.03 Mn |